FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005272275> ?p ?o ?g. }

• W2005272275 endingPage "593" @default.
• W2005272275 startingPage "586" @default.
• W2005272275 abstract "( Cancer Sci 2010; 101: 586–593) The glycan molecules that preferentially appear in cancers are clinically utilized as serum tumor markers. The exact reason, however, why glycans are useful as tumor markers remain elusive. Here, we will summarize lessons learned from well‐established cancer‐associated glycans, and propose strategies to develop new cancer markers. Our recent results on cancer‐associated glycans, sialyl Lewis A and sialyl Lewis X, indicated that the repressed transcription of some glycan genes by epigenetic silencing during early carcinogenesis, and the transcriptional induction of some other glycan genes by tumor hypoxia accompanying cancer progression at locally advanced stages, are two major factors determining cancer‐associated glycan expression. Multiple genes are involved in glycan synthesis, and epigenetic silencing of a part of such genes leads to accumulation of glycans having truncated incomplete structures, which are readily detected by specific antibodies. Glycans are very unique and advantageous as marker molecules because they are capable of reflecting epigenetic silencing in their structures. Transcriptional induction of some glycan genes by tumor hypoxia at the later stages produces further glycan modifications, such as an unusual increase of the N ‐glycolyl sialic acid residues in the glycan molecules. The entire process of malignant transformation thus creates abnormal glycans, whose structures reveal the effects of both epigenetic silencing and tumor hypoxia. The second advantage of a glycan marker over a proteinous marker is that they can reflect the plurality of genetic anomalies in a singular molecule, as it is synthesized by the cooperative action of multiple genes. Glycans are sometimes covalently bound to well‐known cancer‐associated proteins, such as CD44v, and this eventually contributes to a high cancer specificity and functional relevancy in cancer progression." @default.
• W2005272275 created "2016-06-24" @default.
• W2005272275 creator A5018250653 @default.
• W2005272275 creator A5027786827 @default.
• W2005272275 creator A5039466698 @default.
• W2005272275 creator A5052247485 @default.
• W2005272275 creator A5053916898 @default.
• W2005272275 creator A5080351759 @default.
• W2005272275 creator A5089047407 @default.
• W2005272275 date "2010-02-17" @default.
• W2005272275 modified "2023-10-18" @default.
• W2005272275 title "Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers" @default.
• W2005272275 cites W1964130399 @default.
• W2005272275 cites W1966798186 @default.
• W2005272275 cites W1979077832 @default.
• W2005272275 cites W1984710781 @default.
• W2005272275 cites W1986424092 @default.
• W2005272275 cites W1987640672 @default.
• W2005272275 cites W1988638970 @default.
• W2005272275 cites W1991593966 @default.
• W2005272275 cites W1994230235 @default.
• W2005272275 cites W1996912052 @default.
• W2005272275 cites W2008545486 @default.
• W2005272275 cites W2020785063 @default.
• W2005272275 cites W2023094207 @default.
• W2005272275 cites W2026652423 @default.
• W2005272275 cites W2029868343 @default.
• W2005272275 cites W2031346959 @default.
• W2005272275 cites W2032500498 @default.
• W2005272275 cites W2044896527 @default.
• W2005272275 cites W2050983302 @default.
• W2005272275 cites W2062396927 @default.
• W2005272275 cites W2064505748 @default.
• W2005272275 cites W2067845342 @default.
• W2005272275 cites W2078854573 @default.
• W2005272275 cites W2089886187 @default.
• W2005272275 cites W2092766186 @default.
• W2005272275 cites W2094172340 @default.
• W2005272275 cites W2094238516 @default.
• W2005272275 cites W2095484461 @default.
• W2005272275 cites W2102416115 @default.
• W2005272275 cites W2112689808 @default.
• W2005272275 cites W2116060868 @default.
• W2005272275 cites W2124317124 @default.
• W2005272275 cites W2136138562 @default.
• W2005272275 cites W2137463275 @default.
• W2005272275 cites W2153038394 @default.
• W2005272275 cites W2153211813 @default.
• W2005272275 cites W2154719999 @default.
• W2005272275 cites W2163219838 @default.
• W2005272275 cites W2167111828 @default.
• W2005272275 cites W2170274776 @default.
• W2005272275 cites W2318725054 @default.
• W2005272275 cites W305724154 @default.
• W2005272275 doi "https://doi.org/10.1111/j.1349-7006.2009.01455.x" @default.
• W2005272275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20085584" @default.
• W2005272275 hasPublicationYear "2010" @default.
• W2005272275 type Work @default.
• W2005272275 sameAs 2005272275 @default.
• W2005272275 citedByCount "81" @default.
• W2005272275 countsByYear W20052722752012 @default.
• W2005272275 countsByYear W20052722752013 @default.
• W2005272275 countsByYear W20052722752014 @default.
• W2005272275 countsByYear W20052722752015 @default.
• W2005272275 countsByYear W20052722752016 @default.
• W2005272275 countsByYear W20052722752017 @default.
• W2005272275 countsByYear W20052722752018 @default.
• W2005272275 countsByYear W20052722752019 @default.
• W2005272275 countsByYear W20052722752020 @default.
• W2005272275 countsByYear W20052722752021 @default.
• W2005272275 countsByYear W20052722752022 @default.
• W2005272275 countsByYear W20052722752023 @default.
• W2005272275 crossrefType "journal-article" @default.
• W2005272275 hasAuthorship W2005272275A5018250653 @default.
• W2005272275 hasAuthorship W2005272275A5027786827 @default.
• W2005272275 hasAuthorship W2005272275A5039466698 @default.
• W2005272275 hasAuthorship W2005272275A5052247485 @default.
• W2005272275 hasAuthorship W2005272275A5053916898 @default.
• W2005272275 hasAuthorship W2005272275A5080351759 @default.
• W2005272275 hasAuthorship W2005272275A5089047407 @default.
• W2005272275 hasBestOaLocation W20052722751 @default.
• W2005272275 hasConcept C104317684 @default.
• W2005272275 hasConcept C108625454 @default.
• W2005272275 hasConcept C119056186 @default.
• W2005272275 hasConcept C121608353 @default.
• W2005272275 hasConcept C150194340 @default.
• W2005272275 hasConcept C162317418 @default.
• W2005272275 hasConcept C206212055 @default.
• W2005272275 hasConcept C2779256057 @default.
• W2005272275 hasConcept C41091548 @default.
• W2005272275 hasConcept C502942594 @default.
• W2005272275 hasConcept C54355233 @default.
• W2005272275 hasConcept C555283112 @default.
• W2005272275 hasConcept C86803240 @default.
• W2005272275 hasConceptScore W2005272275C104317684 @default.
• W2005272275 hasConceptScore W2005272275C108625454 @default.
• W2005272275 hasConceptScore W2005272275C119056186 @default.
• W2005272275 hasConceptScore W2005272275C121608353 @default.

• next